High-dose diazepam and dyskinesia in anti-NMDA receptor encephalitis

Takeaway

  • High-dose enteral diazepam treatment improved dyskinesia severity in patients with anti-NMDA receptor (NMDAR) encephalitis, with no significant side-effects.

Why this matters

  • Dyskinesia is a common symptom of NMDAR encephalitis (autoimmune disorder, caused by IgG antibodies against the NR1 NMDA receptor subunit) for which there is no standard treatment; however, diazepam has been used to treat other movement disorders and is generally well-tolerated, prompting researchers to assess its efficacy in this patient cohort.

  • Diazepam’s efficacy and safety in NMDAR encephalitis-linked dyskinesia constitutes a reliable starting point for further trials to both confirm these findings and assess its long- term effects in this patient cohort.

International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.